"In the past, if I was lucky, I could fully test one compound for full dose responses on one ion channel in one day. Now I can test eight compounds on three ion channels and get full dose responses. It’s a huge difference"
Nina Ottosson, Senior Research Coordinator, Linköping University, Department of Biomedical and Clinical Sciences, Division of Neurobiology
"We let Qube 384 run our large screening campaigns unattended during the night, so we can develop new assays on the same instruments during the day"
Juha Kammonen, Charles River Laboratories, Senior Research Leader Early Discovery
"For over a decade, we have used Sophion QPatch to support hit-to-lead and lead optimization, in addition to cardiac safety profiling. The addition of a QPatch II and a Qube 384 upgrades and extends our capacity for these efforts and now adds a Sophion platform for electrophysiology-based high-throughput screening.